Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Incidence Risk Variables for Lung Cancer Patients with Bone Metastases

Lee Wang

Utilizing the Surveillance, Epidemiology, and End Results (SEER) database to examine the homogeneous and heterogeneous risk factors for occurrence and prognosis in lung cancer patients with bone metastasis (BM). Between 2010 and 2015, the SEER database analyzed the medical records of lung cancer patients with or without bone metastasis. A multivariate Cox regression was used to determine the prognostic effects of each variable on survival, and a multivariate logistic regression was used to identify risk factors. The SEER database contained 34,585 eligible patients who were included in the analysis. Male gender and liver metastasis were positively associated with a risk of bone metastasis in lung cancer patients, as was the prognosis of the disease. Adenocarcinoma, metastasis to the brain, a younger age, a lower grade of tumor differentiation, a higher N stage (N3), and a risk of BM were all positively correlated with an unfavorable prognosis. For the prognosis of bone metastasis, age, race, marital status, tumor size, and pathologic type were independent risk factors. A rate of 25.9% of lung cancer patients experience bone metastasis-related morbidity. This study's estimates of the homogeneous and heterogeneous risk factors for lung cancer patients' incidence and prognosis of bone metastasis may serve as clinical guidelines for doctors.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié.